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Background/aim: The distribution and the demographic, etiological, and clinical features of autoimmune bullous diseases (ABDs) vary
according to geographic regions of the world. The limited number of reported studies in Turkey are mostly retrospective and generally
include only pemphigus. The aim of our study was to evaluate the demographic data, clinical features, associated triggering factors, and
comorbidities in patients newly diagnosed with ABDs.
Materials and methods: In this descriptive and prospective study, the demographic data, inhabited regions, smoking and drinking
habits, presence of comorbidities, and specific and general potential triggering factors of ABDs considered by the patients were
examined. Furthermore, the distribution of lesions and autoimmune bullous skin disorder intensity scores were recorded.
Results: Of the total 59 ABD patients, 26 (44.1%) were diagnosed with pemphigus, 25 (42.4%) were diagnosed with pemphigoid, and
8 (13.5%) were diagnosed with dermatitis herpetiformis. Although there were some differences between the subgroups of ABDs, the
onset of the disease was associated with a triggering factor (stress, foods, physical trauma, chemical agents, ultraviolet rays, medications,
infections, malignancies, and pregnancy, in a decreasing frequency) in 96.6% of the patients. Autoimmune diseases, neuropsychiatric
disorders, diabetes mellitus, and hypertension were found to be statistically significantly higher in the pemphigoid group compared to
the pemphigus and dermatitis herpetiformis groups.
Conclusion: Evaluation of triggering factors and comorbidities before starting treatment may assist in controlling the disease more
swiftly and reducing the side effects of treatment in the management of ABDs. However, to evaluate the frequency and significance of
our findings in order to determine whether they are statistically significant or not, we suggest a multicenter prospective clinical trial,
which would include control groups and a higher number of patients for each of the disease groups and clinical subtypes.
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1 .Introduction
Autoimmune bullous diseases (ABDs) are a group of
rarely seen organ-specific diseases caused by pathogenic
autoantibodies against target antigens that function in the
intercellular or the mesenchymal/dermal junction of the
epidermis. Clinically, ABDs display quite a wide spectrum
of vesicle or bulla formations on the skin and/or the mucous
membranes. ABDs are classified mainly as intraepidermal
bullous disease (pemphigus) and subepidermal bullous
diseases (pemphigoid, dermatitis herpetiformis, and
acquired epidermolysis bullosa), according to the depth of
blister formation on the skin and types of autoantibodies
against structural proteins (1). Generally, pemphigus
vulgaris (PV) and bullous pemphigoid (BP) form the
greater portion of ABDs, and therefore they are the most
frequently known ABDs (1,2).
* Correspondence: sevgi.akarsu@deu.edu.tr
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The demographic, clinical, and etiological
characteristics of ABDs and the incidence of subgroups
vary according to geographic regions (1,2). In Turkey,
despite the absence of national data, the first annual
incidence estimations in the Mediterranean and Aegean
regions of the country were reported as 2.4 and 1.8 per
million by Uzun et al. and Bozdag and Bilgin, respectively
(3,4). However, it was observed that these limited
numbers of published data were of retrospective nature
and focused on pemphigus only (3–5). Nevertheless,
one of the two recently published retrospective studies
from Turkey covered pemphigus with other ABDs, and
the other included patients with hereditary bullous
diseases and other ABDs (6,7). In this study we aimed to
evaluate demographic data, clinical characteristics, related
triggering factors, and comorbidities of newly diagnosed
patients with ABDs at our clinic.
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2 .Materials and methods
In this prospective-descriptive study that was conducted
between September 2011 and March 2015, the study
groups were selected from among patients who were
newly diagnosed with an ABD based on clinical,
histopathological, and direct immunofluorescence (DIF)
investigation findings. Patients with negative DIF test
results and patients with impaired cognitive functions
who could not answer the questionnaire were excluded
from the study. Sex, age, age at onset of disease, the
interval between the first complaint and the diagnosis,
place of residence (rural or urban), family history, tobacco
and alcohol habits (three groups: active smoker before
the disease onset, former smoker but nonactive in the
last 6 months, nonsmoker), triggering factors described
by patients, and specific triggering factors of ABDs (e.g.,
medication, ultraviolet exposure, nutritional factors,
chemical agent exposure, topical applications, infections,
vaccination, emotional stress, trauma, malignancy, and/or
radiotherapy history) were examined with a standardized
questionnaire form. It was determined whether the drugs
that were still in use had triggering properties (8–11).
Autoimmune Bullous Skin Disorder Intensity Scores
(ABSISs) with localization and distribution of lesions were
recorded following dermatological examinations (12). In
addition to the questionnaires, laboratory, radiology, and
pathology test results and clinical notes of patients recorded
in the hospital system were taken into consideration to
determine the comorbidities. Local ethics committee
approval was obtained prior to commencing the study,
and all volunteers read and signed an informed consent
form. The data were analyzed by SPSS 15; numerical
variables were given as mean ± standard deviation (SD)
by descriptive analysis and other variables were presented
as incidence in percentages. The chi-square test, Fisher’s
exact test, Mann–Whitney U test, and Kruskal–Wallis
test were used in the determination of demographic and
clinical characteristics of the patients. The values were
accepted as statistically significant at P < 0.05.
3 .Results
A total of 59 patients newly diagnosed with an ABD were
recruited for the study. Of the total number, 26 patients
(44.1%) were diagnosed with pemphigus, 25 (42.4%)
patients were diagnosed with pemphigoid, and 8 (13.5%)
patients were diagnosed with dermatitis herpetiformis
(DH). Of the 26 patients with pemphigus, 20 (76.9%)
had PV and 6 (23.1%) had pemphigus foliaceus; of the 25
patients with pemphigoid, 21 (84%) had BP and 4 (16%)
had mucous membrane pemphigoid. Table 1 provides the
distribution of demographics and clinical characteristics.
The mean age ± SD of patients was 58.42 ± 19.14 years;
39 (66.1%) were female and 20 (33.9%) were male. There

was no difference between the subgroups in terms of sex
distribution, but the mean age at the onset of disease (P =
0.008) and the age at diagnosis (P = 0.008) were statistically
significantly higher in the pemphigoid group compared to
the pemphigus group. However, the mean delay time in
diagnosis was highest in the DH group when compared
with both the pemphigus and the pemphigoid group (P
< 0.001).
In the pemphigus group, the initial localization of
the lesions was the mucous membranes (P = 0.001),
while it was the skin in the pemphigoid and DH groups
(P = 0.001). When considering the localization and
distribution of existing lesions, isolated skin involvement
was significantly lower and mucosal distribution was
generally higher in the pemphigus group (P = 0.004 and P
= 0.017, respectively). Extremity lesions were significantly
more common in the pemphigoid and the DH groups than
in the pemphigus group (P = 0.002). When comparing the
three groups according to ABSISs, there was no significant
difference between the groups in terms of the extent of skin
involvement, but the extent and severity scores of the oral
lesions were significantly higher in the pemphigus group
(P = 0.004 and P = 0.01, respectively) (Table 1).
The triggering factors that may play a role in the
etiology of ABDs are presented in Table 2. Although
there was no significant difference between the groups,
most of the patients lived in rural areas and in the Aegean
region. The most frequent geographical distributions
after the Aegean region were East and Southeast Anatolia
for the pemphigus group, Central and East Anatolia for
the pemphigoid group, and the Marmara and Southeast
Anatolia regions for the DH group. None of the patients
had a family history of ABD. There was no tobacco or
alcohol use in the vast majority of the groups and there
was no statistically significant difference between the three
groups. When the patients were questioned in terms of
personal triggering factors as described by themselves,
physical trauma was blamed to a higher extent in the
pemphigus group compared to the pemphigoid group (P
= 0.015). When asked about triggering foods, they were
tomato in 6 (23.1%); garlic in 4 (15.3%); onion, orange,
and black pepper in 3 (11.5%); leek, banana, and red
pepper in 2 (7.7%); and strawberry, grape, iodized salt,
and sea fish in 1 (3.8%) of the 26 pemphigus patients.
They were tomato in 4 (16%) and garlic and iodized salt
in 1 (4%) of the 25 pemphigoid patients and tomato and
milk in 1 (12.5%) of the DH patients. When considering
chemicals, they were pesticides in 3 (11.5%) and dyes in
1 (3.8%) of the patients in the pemphigus group. They
were house-cleaning products and mineral oil in 2 (8) and
waste, pesticides, and chalk dust in 1 (4%) of the patients
in the pemphigoid group and house-cleaning products
in 1 (12.5%) of the DH patients. Additionally, two (7.7%)
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20 (76.9%)
12 (46.2%)
10 (38.4%)
14 (53.9%)
16 (61.6%)

37.7 ± 27.3 (1–90)
26.2 ± 28.6 (0–89)
2.7 ± 2.4 (0–8)
10.0 ± 11.2 (0–32)

Distribution of existing lesions
Trunk
Extremity
Head and neck
Scalp
Mucosa

ABSIS, mean ± SD (min–max)
Total ABSIS
Extent of skin involvement
Extent of oral involvement
Severity of oral involvement
40.5 ± 29.7 (1–90)
27.8 ± 30.8 (0–89)
2.7 ± 2.4 (0–8)
10.0 ± 11.2 (0–32)

14 (70%)
7 (35%)
5 (25%)
9 (45%)
15 (75%)

5 (25%)
3 (15%)
12 (60%)

6 (30%)
14 (70%)

2.5 ± 1.3 (1–5)

50.5 ± 16.1 (16–73)

50.2 ± 13.9 (17–73)

14 (70%)
6 (30%)

20 (33.9%)

28.5 ± 15.6 (0–55)
28.5 ± 15.6 (0–55)
0 (0%)
0 (0%)

6 (100%)
5 (83.3%)
5 (83.3%)
5 (83.3%)
1 (16.7%)

5 (83.3%)
0 (0%)
1 (16.7%)

5 (83.3%)
1 (16.7%)

5.1 ± 10.2 (1–12)

51.8 ± 11.3 (35–64)

53.0 ± 19.0 (16–69)

3 (50%)
3 (50%)

6 (10.3%)

39.7 ± 24.4 (0–84)
36.4 ± 23.7 (0–84)
0.8 ± 1.6 (0–6)
2.4 ± 5.8 (0–24)

17 (68%)
21 (84%)
7 (28%)
6 (24%)
9 (36%)

16 (64%)
3 (12%)
6 (24%)

21 (84%)
4 (16%)

7.8 ± 11.4 (1–48)

66.4 ± 20.2 (20–90)

66.7 ± 20.1 (20–90)

17 (68%)
8 (32%)

25 (42.4%)

40.26 ± 25.6 (0–84)
36.8 ± 24.2 (0–84)
0.6 ± 1.3 (0–5)
2.7 ± 6.3 (0–24)

14 (66.7%)
18 (85.7%)
7 (33.3%)
6 (28.6%)
6 (28.6%)

15 (71.4%)
2 (9.5%)
4 (19.1%)

20 (95.2%)
1 (4.8%)

3.9 ± 2.8 (1–10)

67.3 ± 19.7 (20–90)

67.3 ± 19.7 (20–90)

14 (66.7%)
7 (33.3%)

21 (35.6%)

BP

37.0 ± 19.4 (0–53)
34.5 ± 24.1 (0–53)
1.5 ± 3.0 (0–6)
1.0 ± 2.0 (0–4)

3 (75%)
3 (75%)
0 (0%)
0 (0%)
3 (75%)

1 (25%)
1 (25%)
2 (50%)

1 (25%)
3 (75%)

28.5 ± 17.9 (6–48)

61.5 ± 25.5 (26–83)

63.7 ± 25.4 (28–83)

3 (75%)
1 (25%)

4 (6.8%)

MMP

39.7 ± 14.5 (21–64)
39.7 ± 14.5 (21–64)
0 (0%)
0 (0%)

8 (100%)
8 (100%)
3 (37.5%)
3 (37.5%)
0 (0%)

8 (100%)
0 (0%)
0 (0%)

8 (100%)
0 (0%)

18.2 ± 14.1 (3–48)

56.7 ± 20.7 (31–86)

56.8 ± 19.6 (33–84)

5 (62.5%)
3 (37.5%)

8 (13.5%)

Dermatitis
herpetiformis

* = Statistically significant characteristics according to the comparisons between the pemphigus, pemphigoid, and dermatitis herpetiformis groups.

PV = Pemphigus vulgaris; PF = pemphigus foliaceus; BP = bullous pemphigoid; MMP = mucous membrane pemphigoid; n = number of patients; ABSIS = Autoimmune Bullous Skin Disorder Intensity Score.

10 (38.4%)
3 (11.6%)
13 (50%)

Localization of existing lesions
Skin
Mucosa
Skin + mucosa

3.4 ± 2.5 (1–12)

Delay time in diagnosis, month,
mean ± SD (min–max)

11 (42.3%)
15 (57.7%)

50.8 ± 14.9 (16–73)

Age at disease onset, years,
mean ± SD (min–max)

Localization of initial lesions
Skin
Mucosa

50.8 ± 14.9 (16 –73)

17 (65.4%)
9 (34.6%)

Sex
Female
Male

Age at diagnosis, years,
mean ± SD (min–max)

26 (44.1%)

Total pemphigoid

Total pemphigus

PF

Pemphigoid group

Pemphigus group
PV

Newly diagnosed autoimmune bullous diseases (n = 59)

Number of patients

Features,
n (%)

Table 1. Demographic and clinical characteristics of autoimmune bullous diseases.

0.597
0.109
0.004 *
0.010 *

0.184
0.002 *
0.567
0.163
0.017 *

0.004 *
0.960
0.111

0.001 *
0.001 *

< 0.001 *

0.008 *

0.008 *

0.956

-

P-value
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Table 2. Possible triggering factors in autoimmune bullous diseases.
All ABD patients
(n = 59)

Pemphigus group
(n = 26)

Pemphigoid group
(n = 25)

Dermatitis
herpetiformis
(n = 8)

P-value

Hometown
Aegean Region
Marmara Region
Mediterranean Region
Black Sea Region
Central Anatolia Region
Eastern Anatolia Region
Southeastern Anatolia Region

36 (61%)
3 (5.1%)
2 (3.4%)
2 (3.4%)
4 (6.8%)
9 (15.3%)
3 (5.1%)

15 (57.7%)
1 (3.8%)
0 (0%)
1 (3.8%)
1 (3.8%)
6 (23.1%)
2 (7.7%)

15 (60%)
1 (4%)
2 (8%)
1 (4%)
3 (12%)
3 (12%)
0 (0%)

6 (75%)
1 (12.5%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
1 (12.5%)

0.678
1.000
1.000
0.350
0.243
1.000

Urban/rural inhabitance

52 (88.1%)/7 (11.9%)

23 (88.5%)/3 (11.5%)

22 (88.0%)/3 (12.0%)

7 (87.5%)/1 (12.5%)

0.997

Smoking habit
Never smoked
Quit smoking
Active smoker
Pack-years, mean ± SD (min–max)

39 (66.1%)
10 (16.9%)
10 (16.9%)
26.5 ± 17.5 (7–49)

15 (57.7%)
6 (23%)
5 (19.2%)
30.8 ± 17.1 (10–49)

19 (76%)
3 (12%)
3 (12%)
19.0 ± 18.2 (7–40)

5 (62.5%)
1 (12.5%)
2 (25%)
27.0 ± 25.4 (9–45)

0.382
0.593
0.643
0.472

Alcohol consumption
Temperance
Quit
Active drinker
Glasses/month, mean ± SD (min–max)

44 (74.6%)
4 (6.7%)
11 (18.6%)
5.54 ± 8.38 (1–30)

16 (61.5%)
4 (15.3%)
6 (23.1%)
8.16 ± 10.98 (1–30)

22 (88%)
0 (0%)
3 (12%)
3.0 ± 1.73 (2–5)

6 (75%)
0 (0%)
2 (25%)
1.50 ± 0.70 (1–2)

0.099
0.534
0.069
0.299

Possible triggering factors
Stress
Foods
Physical trauma
Chemical agents
Ultraviolet rays
Drugs
Infections
Malignancy
Pregnancy
Others

57 (96.6%)
51 (86.4%)
18 (30.5%)
13 (22%)
11 (18.6%)
9 (15.2%)
8 (13.6%)
4 (6.8%)
2 (3.4%)
1 (1.7%)
4 (6.8%)

26 (100%)
25 (96.2%)
12 (46.2%)
11 (42.3%)
3 (11.5%)
6 (23.1%)
2 (7.7%)
2 (7.7%)
1 (3.8%)
1 (3.8%)
1 (3.8%)

24 (96%)
19 (76%)
4 (16%)
3 (12%)
7 (28%)
2 (8%)
6 (24%)
2 (8%)
1 (4%)
0 (0%)
2 (8%)

7 (87.5%)
7 (87.5%)
1 (12.5%)
0 (0%)
1 (12.5%)
1 (12.5%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
1 (12.5%)

0.232
0.114
0.064
0.015 *
0.143
0.248
0.140
1.000
1.000
0.256

Triggering drug use

12 (20.3%)

1 (3.8%)

11 (44%)

0 (0%)

0.001 *

Characteristics, n (%)

n = Number of patients; * = statistically significant characteristics according to the comparisons between the pemphigus, pemphigoid, and dermatitis herpetiformis groups.

of the pemphigus patients had upper respiratory tract
infections and 2 (8%) of the pemphigoid patients had
urinary tract infections at the time of the research, and
these infections were considered to be a trigger according
to the patients. Drugs that may possibly have been triggers
according to the patients were metoprolol in 1 (3.8%) and
paracetamol in another patient in the pemphigus group,
and furosemide in 2 (8%) and pramipexole in another
patient (4%) in the pemphigoid group. When considering
the triggering drugs described in literature, of the 11
(44%) patients with pemphigoid, it was associated with
acetylsalicylic acid in 4 (16%), furosemide in 3 (12%),
ramipril in 2 (8%), and amlodipin in 2 (8%), whereas there
were only diclofenac and acetylsalicylic acid in one (3.8%)
patient in the pemphigus group (P = 0.001). Furthermore,
alcohol use was a triggering factor according to 1 (3.8%)
patient in the pemphigus group, tobacco and alcohol use
in 1 (4%) patient in the pemphigoid group, and pollen
allergy in 1 (12.5%) patient in the DH group.

When comparing comorbid diseases, autoimmune
diseases, neuropsychiatric disorders, diabetes mellitus, and
hypertension were significantly higher in the pemphigoid
group. With regard to malignancies, multiple myeloma in 1
(3.8%) and meningioma in another patient were determined
in the pemphigus group, while chronic myeloproliferative
disease was determined in 2 (8%), adrenal incidentaloma
in 1 (4%), and adrenal carcinoma in another patient in the
pemphigoid group. Although it did not show a statistical
significance, the frequency of urinary tract infection
was higher in the pemphigoid group and herpes virus
infections were higher in the pemphigus group (herpetic
gingivostomatitis in one patient and eczema herpeticum in
another) at the time of diagnosis. Serological markers for
celiac disease (CD) were positive in all DH patients, but
gastrointestinal complaints were recorded only in one patient
(12.5%) and CD was determined in 3 (37.5%) patients after
small intestinal biopsy. The comorbidities in patients with
ABDs are presented in Table 3.

835

AKARSU et al. / Turk J Med Sci
Table 3. Comorbidity profiles of patients with autoimmune bullous diseases.
Comorbidities, n (%)

All ABD patients
(n = 59)

Pemphigus group
(n = 26)

Pemphigoid group
(n = 25)

Dermatitis
herpetiformis
(n = 8)

P-value

Autoimmune diseases
Diabetes mellitus
Rheumatoid arthritis
Hypothyroidism
Hyperthyroidism
Celiac disease
Malignancy
Hematological
Solid organ
Neuropsychiatric disorder
Cerebrovascular occlusion
Depression
Dementia
Alzheimer disease
Multiple sclerosis
Parkinson disease
Schizophrenia
Vertigo
Paresthesia
Infections
Herpes simplex virus infection
Oral candidiasis
Secondary impetiginization
Upper respiratory tract infection
Lower respiratory tract infection
Urinary tract infection
Others
Hypertension
Coronary artery disease
Chronic renal failure
Chronic obstructive pulmonary disease

25 (42.4%)
17 28.8%)
2 (3.4%)
6 (10.2%)
1 (1.7%)
3 (5.1%)
6 (10.1%)
3 (5.1%)
3 (5.1%)
18 (30.5%)
3 (5.1%)
4 (6.8%)
2 (3.4%)
2 (3.4%)
2 (3.4%)
1 (1.7%)
1 (1.7%)
1 (1.7%)
1 (1.7%)
17 (28.8%)
3 (5.1%)
1 (1.7%)
4 (6.8%)
2 (3.4%)
3 (5.1%)
5 (8.5%)

5 (19.2%)
3 (11.5%)
1 (3.8%)
2 (7.7%)
0 (0%)
0 (0%)
2 (7.6%)
1 (3.8%)
1 (3.8%)
2 (7.7%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
1 (3.8%)
0 (0%)
1 (3.8%)
0 (0%)
0 (0%)
7 (23.1%)
2 (7.7%)
1 (3.8%)
1 (3.8%)
0 (0%)
1 (3.8%)
1 (3.8%)

16 (64%)
12 (48%)
0 (0%)
3 (12%)
1 (4%)
0 (0%)
4 (16%)
2 (8%)
2 (8%)
15 (60%)
3 (12%)
3 (12%)
2 (8%)
2 (8%)
1 (4%)
1 (4%)
0 (0%)
1 (4%)
1 (4%)
10 (40%)
1 (4%)
0 (0%)
3 (12%)
2 (8%)
0 (0%)
4 (16%)

4 (50%)
2 (25%)
1 (12.5%)
1 (12.5%)
0 (0%)
3 (37.5%)
0 (0%)
0 (0%)
0 (0%)
1 (12.5%)
0 (0%)
1 (12.5%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
2 (25%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
2 (25%)
0 (0%)

0.005 *
0.017 *
0.668
0.191
0.017 *
0.327
-

22 (37.3%)
2 (3.4%)
2 (3.4%)
2 (3.4%)

3 (11.5%)
1 (3.8%)
0 (0%)
0 (0%)

16 (64%)
1 (4%)
2 (8%)
2 (8%)

3 (37.5%)
0 (0%)
0 (0%)
0 (0%)

0.001 *
-

n = Number of patients; * = statistically significant characteristics according to the comparisons between the pemphigus, pemphigoid, and dermatitis herpetiformis groups.

4 .Discussion
Patients diagnosed with an ABD in our clinic between 2011
and 2015 were mostly in the pemphigus and pemphigoid
groups at very close rates, and in the DH group at the
lowest rate. In the literature, BP was reported as the
most frequent ABD in developed countries, but in our
country, it was the second most common ABD after PV.
A significant increase in the number of patients has also
been noted in recent years, probably due to prolongation
of the lifespan (3,6,7). Furthermore, the PV/BP ratio in our
study was 0.96, and this ratio was reported to be between
1.1–1.5 in previous reports from Turkey. Although the
demographic and clinical characteristics of ABD patients
were in accordance with previous studies, most of the
DH patients in our study were female (3,6,7,10,13). It is
known that DH affects males more frequently, but the
predominance of female patients was also reported if there
was an accompanying autoimmune disease, as in our study
(10,13). In the literature, in order to show the effect of the
place of birth and the living area, studies were limited
to pemphigus. Wohl et al. found that two-thirds of their
study patients lived in urban regions (14). In a study from
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Turkey it was shown that half of the patients were from
the eastern region of Anatolia (5). In our study, the place
of birth and the living characteristics were found to be in
accordance with the literature reports.
It was considered that genetic, immunological,
and infectious conditions possibly play a role in
the etiopathogenesis of ABDs. Although comorbid
inflammatory and infectious conditions, malignancies,
and endocrinological disorders have been mentioned
in some patients in the literature, exogenous triggering
factors may also play a role in the etiology of ABDs by
regulating the immune response or by changing the
antigenic properties of the epidermal basal membrane.
Determining and removing these factors may aid in the
prevention of exacerbations of the disease (8–11,15). In
this study, it was aimed to determine the triggering factors
and comorbidities in newly diagnosed ABD patients in
order to control the disease in a rapid way and to decrease
morbidities. Although there were some differences
between the ABD groups, the onset of the disease was
associated with a stimulating factor (stress, foods, physical
trauma, chemical agents, ultraviolet rays, drugs, infections,
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malignancy, and pregnancy, in decreasing frequency)
in 96.6% of the patients. It was observed that physical
trauma was blamed to a significantly higher extent in
the pemphigus group, and use of a triggering drug was
determined to be significantly higher in the pemphigoid
group. When considering the frequency of comorbidities,
hypertension, diabetes mellitus, and infections were
determined to be high in all three groups. However,
hypertension, autoimmune diseases, diabetes mellitus,
and neuropsychiatric disorders were significantly higher
in the pemphigoid group.
When reviewing the literature for previous studies that
have examined the triggering factors of ABDs, it was found
that drug use (thiol and phenol groups) was the most
frequently investigated issue in pemphigus. Moreover,
it was mentioned that some viral infections (especially
herpetic infections), physical factors (most frequently
ultraviolet rays and trauma), pregnancies, and emotional
stress may play a role in the etiology of pemphigus (8).
Although nutritional factors have rarely been mentioned,
previous epidemiologic, clinical, and experimental data
support the belief that some nutrients with chemical
structures similar to those of certain pemphigus-inducing
drugs may actually have acantholytic potential over time
via biochemical and/or antibody-mediated immunologic
mechanisms. These substances may either be incorporated
into keratinocytes or may release sequestered desmoglein
antigens from immunologically privileged sites, and may
also interfere with immune balance. It has been suggested
that vegetables in the genus Allium that are rich in thiol
(like onion, garlic, leek, and chive) and foods in the tannin
group that are rich in phenol (like black pepper, red pepper,
sweet cherry, raspberry, cranberry, blackberry, mango,
avocado, peach, cashew nuts, ginger, ginseng, red wine,
tea, vanillin, cacao), isothiocyanate (like mustard, radish,
cauliflower, broccoli, turnip, cabbage, kale), phycocyanins
(blue-green algae such as Spirulina platensis), and cinnamic
acid (like tomato, grape, orange) may trigger pemphigus
(8,11). Tsankov et al. found an association between disease
activity and triggering factors in 42% of their pemphigus
patients, and they reported stress as the most frequent
triggering factor (16). In the study conducted by Brenner
et al., they aimed to examine environmental factors for
126 pemphigus patients from seven different countries
and they found that smoking was a protective factor,
while exposure to garden materials, pesticides, solvents,
and metal vapor; chronic wound history; drug reactions;
and pregnancies were determined to be higher in the
patients than in the control group (17). Wohl et al. found
a significant relationship with exposure to ultraviolet rays,
pesticides, and garden materials and consumption of spicy
food in their study, but they did not find any relation with
drug use, emotional stress, comorbidity, pregnancy, or
hormone use (14). In a study from Turkey it was shown that

working in animal husbandry and farming, not smoking,
multiple pregnancies, and psychological stress may be
triggering factors. No relationship was found with food
and drinks in the study, but only tea, coffee, and spicy and
bitter foods were examined among foods and drinks (5).
Although there was no control group in our study, most
of the pemphigus patients were nonsmokers and it was
observed that emotional stress and exposure to chemicals,
especially to pesticides, may be aggravating factors, as
mentioned in the literature. In addition, pemphigus was
found to be related to certain foods including Allium
species and those containing tannin and cinnamic acid in
our patients. In the literature, the role of exogenous triggers
in pemphigoid was found at a rate of 15%–66%. In the
first reports, when only systemic drugs were investigated,
physical factors (such as local trauma, ultraviolet rays, and
radiotherapy), infections, and vaccinations also began to
be reported (9). The most identified drugs were diuretics,
angiotensin-converting enzyme inhibitors, acetylsalicylic
acid, and benzodiazepines (7,9,18,19). Although it was at
a low percentage when compared to the study conducted
by Daye et al., in our study, a relationship between the use
of drugs and disease onset was determined in 24% of BP
patients, and triggering drug use was determined in 44%
of BP patients (7). In the literature, in one dyshidrosiform
pemphigoid patient who described nutritional factors as
the triggering factor, the lesions completely cleared with
a nickel-poor diet. It was also mentioned that there was
no response with gluten-free diets in BP patients in whom
antigliadin antibodies were present in the peripheral blood
(9,11). In our study, tomato was found to be associated
with itching (maybe due to the rich histamine content)
in all of the pemphigoid patients, and garlic was found
to possibly be associated in one of the patients. It was
also considered that due to the similar structure of garlic
to thiol group drugs, it may have a real triggering effect
in our patient (9,20). Furthermore, it was mentioned
by one of our patients that iodized salt had a triggering
effect. It was shown that the use of intravenous, topical,
or expectorant forms of iodide had a triggering effect in
BP patients in certain reports (21). In patients with DH it
was reported that gluten in particular and less often milk
and iodine in the diet, ultraviolet B rays, and repetitive
minor trauma on extensor skin surfaces possibly had an
exacerbating effect (10,13,22). In 22 DH patients reported
by Zhang et al., the lesions had progressed after delivery in
one of them (4.5%) and after intervertebral disc surgery in
another (22). In our study, we found that emotional stress
was the most probable triggering cause. Although possible
triggering effects of tomato and milk were recorded in our
patients, it was interesting that gluten-containing food was
not recorded as a triggering factor, which could be a more
likely food to avoid.

837

AKARSU et al. / Turk J Med Sci
In the literature, it has been mentioned that various
autoimmune diseases, malignancies, neuropsychiatric
disorders, cardiovascular diseases, and infections may
accompany ABDs, despite the possible presence of varieties
in different clinical types (17–19,23). In spite of reports
that cardiovascular diseases were generally associated
with BP, cardiovascular diseases were also associated with
other ABDs in some case reports (13,22,24). Nevertheless,
Marzano at al. reported that the hypercoagulability in
pemphigoid is responsible for the inflammation, bulla
formation, and thrombosis, but there is no increased
risk for thrombosis in patients with pemphigus (24). In
our study, an increased frequency of hypertension was
determined in the pemphigoid group, and furthermore,
cerebrovascular occlusion was determined only in the
pemphigoid group with 3 (12%) patients. It is known
that autoimmune diseases such as diabetes mellitus,
autoimmune thyroid diseases, and connective tissue
diseases can be observed concurrently in the same patient
(1,23). Among our ABD patients, both autoimmune
diseases and diabetes mellitus were significantly more
common in the pemphigoid group. Diabetes mellitus
occurs as an autoimmune response against BP antigens,
which is transformed by the glycosylation of proteins at
the dermo-epidermal junction in pemphigoid patients
(18). In the literature it is reported that the frequency of
autoimmune thyroid disease varies between 0% and 16%
in pemphigus patients (6,25), but in a study conducted by
Uzun et al. it was found that thyroid pathologies were the
most common comorbidities in pemphigus patients (3).
Nonetheless, the most common comorbidity was diabetes
mellitus and then hypothyroidism, with a rate of 7.7%
in our pemphigus study group. It has also been reported
that 10%–49% of DH patients have hypothyroidism and
diabetes mellitus as the most common autoimmune
comorbidities, consistent with our study. Additionally, it
is accepted that all DH patients have CD in theory, due to
sharing a common mechanism, even though they usually
have subclinical gastrointestinal disease and only mild
symptoms. In our DH patients, 37.5% were diagnosed
with CD by histopathological examination, whereas this
was reported as 3.3%–18% in the literature (13,22).
Theoretically, it is expected that deterioration of
the mucocutaneous barrier increases susceptibility to
infection. Esmaili et al. analyzed 155 PV patients and found
associated infections in 61%, including oral candidiasis,
impetiginization, herpes simplex, and urinary tract and
pulmonary tract infections, in decreasing order, but they
determined that these infections were rarer (18.3%) in
patients who had presented to the hospital for the first time
and who did not use immunosuppressive therapy (26). It
was mentioned that systemic infections occurred in half
of BP patients due to the presence of concomitant diseases
and advanced age. Frequent urinary tract infections
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in these patients have been associated with the crossreactivity of autoantibodies against BP with the urinary
bladder epithelium (19,23,27). In our study, urinary tract
infections were also more common in the pemphigoid
group than the other groups. Recently Lehman et al.
showed that the rates of diabetes mellitus, urinary tract
infection, impetiginization, and systemic infections that
required hospitalization in the pemphigoid group were
similar to those of the pemphigus group, but higher than
in the DH group. They also stated that infection risk could
be decreased in most DH patients by keeping patients
under control with a gluten-free diet and dapsone therapy
(27). In our study, although the presence of infection was
higher in the pemphigoid group, there was no statistically
significant difference between the three groups.
In the literature, it has been mentioned that BP is
the most common ABD associated with malignancy;
however, there was no significant increase in malignancy
incidence in large series compared to control groups.
Furthermore, it is still controversial whether both BP
and malignancies tend to increase with age (18,19,23).
In any case, since the malignancy frequency of our BP
patients was similar to those of past publications in the
literature, we think that it would be convenient to conduct
regular malignancy screening in accordance with age
and sex (6,18). In pemphigus, although malignancy is
usually associated with paraneoplastic pemphigus, it is
also rarely seen in other clinical forms. Half of these are
related to the lymphoreticular system, such as thymoma,
lymphoma, and leukemia (23). The relationship between
DH and malignancy is also controversial. It is known
that the frequency of non-Hodgkin lymphomas and
T-cell lymphomas that involve the gastrointestinal tract
is increased in CD patients who have long-term and
untreated disease. However, in recent studies, it was shown
that there is no greater risk for developing lymphoma in
DH patients than in the healthy population (22,23). In
our study, we determined a higher malignancy incidence
in the pemphigoid group compared to the pemphigus
group, but we did not determine any malignancy in the
DH group. However, if we consider the low percentage of
our DH patients and the short follow-up period, we think
that evaluation in large series with a long follow-up period
would be more appropriate.
In recent publications, it has been emphasized
that 36%–55.8% of BP patients exhibit an increased
frequency of certain neuropsychiatric disorders such
as cerebrovascular occlusion, dementia, Parkinson
disease, epilepsy, schizophrenia, multiple sclerosis, and
immobility. It has been considered that the cross-reaction
between the common sequences of different isoforms
of the 230-kDa BP antigen (BPAG1) in the skin and the
neurological system plays a role in the association of
BP and neurological diseases (18,19). Gambichler et
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al. also demonstrated that increased BP180 titers and
blood eosinophils are independent predictors for the
presence of neurological diseases in BP patients (28).
A recent systematic review and metaanalysis provided
support for a significant association between BP and
neurological diseases; therefore, it was recommended
that clinicians should be aware of this association and
manage modifiable risk factors for neurological diseases
accordingly (29). Moreover, it has been emphasized that
25% of patients with DH and gluten enteropathy also
have some neuropsychiatric disorders such as epilepsy,
ataxia, and dementia, and these associations are related
to the neurotoxic effect of gluten (13,23). Additionally,
the presence of a new antispinal antibody was determined
in more than half of DH patients by Wills et al. (30). In
pemphigus, although the pathogenesis is not yet known,
neuropsychiatric diseases such as depression and
obsessive-compulsive disorder have been reported in the
literature (3,23). In our study, rates of neuropsychiatric
disorders were determined to be statistically higher in
the pemphigoid group compared to the other groups, in
accordance with the literature.
The limitations of this study are the small sample
size and the lack of different immunoassays for the

characterization of autoantibody specificity, including
indirect immunofluorescence, immunoblotting, enzymelinked immunosorbent assay, and/or immunoprecipitation
tests, which are declared as necessary in the differential
diagnosis of ABDs. However, we think that the size of our
study group is relatively large when we consider the low
incidence rate of pemphigus in our region according to the
data in the literature (4).
In conclusion, based on the results of our study, we
think that it would be beneficial to treat patients with
a multidisciplinary approach with the cooperation of
dietitians and psychiatrists, while the most common
triggering factors in ABDs are various foods and stress.
In addition, we recommend avoiding trauma and the
changing of triggering drug(s) in pemphigoid patients.
Furthermore, we would like to emphasize the importance
of monitoring hypertension, autoimmune diseases,
diabetes mellitus, neuropsychiatric disorders, and possible
triggering effects of drugs that are being used in the
treatment of comorbidities, especially in pemphigoid
patients. Future prospective multicenter studies with
control groups and standardized timing of follow-up are
warranted.
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